5,856 Shares in Illumina, Inc. $ILMN Purchased by Hanseatic Management Services Inc.

Key Points

• Hanseatic Management Services acquired 5,856 Illumina shares worth approximately $1.6 million, making Illumina 1% of its portfolio. Institutional investors collectively own 89.42% of the company.
• Illumina recently exceeded quarterly earnings and revenue expectations, reporting $1.31 in EPS and $1.16 billion in revenue, with revenue up 9.4% year over year.
• Insider selling remains a risk: Director Keith Meister sold 457,858 shares for roughly $91.6 million, while insiders have sold more than 2 million shares over the past 90 days. Analysts’ consensus rating is “Hold,” with an average price target of $234.41.

Hanseatic Management Services Inc. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,856 shares of the life sciences company's stock, valued at approximately $1,603,000. Illumina comprises 1.0% of Hanseatic Management Services Inc.'s holdings, making the stock its 28th largest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Illumina during the second quarter valued at $3,374,423,000. WCM Investment Management LLC increased its holdings in Illumina by 45.5% in the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA bought a new stake in Illumina in the 2nd quarter valued at $617,981,000. Ninety One UK Ltd lifted its stake in Illumina by 37,920.0% in the 3rd quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company's stock worth $372,198,000 after purchasing an additional 1,356,397 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new stake in Illumina in the 2nd quarter worth $358,652,000. Institutional investors own 89.42% of the company's stock.

Insider Activity at Illumina

In related news, Director Keith Meister sold 457,858 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is currently owned by company insiders.

Illumina Price Performance

ILMN stock opened at $288.79 on Thursday. Illumina, Inc. has a 52 week low of $94.00 and a 52 week high of $309.35. The firm has a market capitalization of $43.61 billion, a P/E ratio of 53.88, a price-to-earnings-growth ratio of 3.82 and a beta of 1.41. The company has a fifty day simple moving average of $247.14 and a two-hundred day simple moving average of $174.99. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.19 EPS. Analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Earnings anticipation supported the stock. Investors are looking for another revenue and adjusted-EPS beat after Illumina exceeded expectations in the second quarter and raised its full-year outlook. Analysts are likely to focus on NovaSeq X demand, clinical sequencing adoption, margins, and updated 2026 guidance. Why Illumina (ILMN) Stock Is Up Today
• Positive Sentiment: Recent operating momentum has improved investor sentiment. The company previously reported year-over-year revenue growth, stronger-than-expected results, and rising demand for its sequencing platforms and clinical applications. Several institutions also increased their Illumina holdings in recent filings, including FMR, PRIMECAP, Wellington, and Ninety One. What to expect from Illumina’s Q3 earnings
• Neutral Sentiment: The upcoming investor conference provides another potential catalyst. Illumina management is scheduled to participate in the Jefferies Global Healthcare Conference on November 17, giving investors an opportunity to hear additional commentary on demand, strategy, and the outlook. Illumina To Webcast Upcoming Investor Conference
• Negative Sentiment: Insider selling and valuation remain risks. Quiver reported 108 open-market insider sales and no purchases over the past six months, including substantial selling by Keith Meister. In addition, the reported median analyst price target of $185 is well below recent trading levels, suggesting limited near-term upside if earnings or guidance disappoint. Why Illumina (ILMN) Stock Is Up Today

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ILMN. Barclays raised their price objective on Illumina from $160.00 to $200.00 and gave the company an "underweight" rating in a research report on Wednesday, October 7th. Weiss Ratings reiterated a "hold (c)" rating on shares of Illumina in a research report on Monday, August 31st. Royal Bank Of Canada boosted their target price on Illumina from $230.00 to $310.00 and gave the stock an "outperform" rating in a research report on Monday, October 5th. Piper Sandler increased their price target on Illumina from $225.00 to $305.00 and gave the company an "overweight" rating in a research note on Monday, September 28th. Finally, Argus raised their price target on Illumina from $180.00 to $235.00 and gave the company a "buy" rating in a report on Thursday, September 3rd. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Illumina currently has an average rating of "Hold" and a consensus target price of $234.41.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.